Cingulate Q2 FY26 net loss widens to $5.87 million; SG&A more than doubles to $3.93 million
CING•Cash position improves
Cash and cash equivalents rose to $28.4 million at June 30 from $11 million at Dec. 31.
Quarterly loss widens as expenses shift
Cingulate posted a Q2 net loss of $5.9 million, widening from $5 million a year earlier.
- Research and development expense fell 44.9% to $1.5 million.
- Selling, general and administrative expense more than doubled to $3.9 million.
Regulatory update and commercial agreement
The FDA issued a complete response letter on June 1 seeking additional CMC information for CTx-1301. The company said no clinical safety or efficacy concerns were cited.
Cingulate also signed an exclusive services agreement with Prasco to set up commercial distribution. The company said cash is expected to fund operations into .
